IL17A and atherosclerosis: Additionally, IL-17 inhibitors have shown superior efficacy over TNF-α inhibitors and IL-12/23 inhibitors in reducing non-calcified plaque burden, suggesting that IL-17 inhibitors may offer added benefits in managing atherosclerosis in this patient population.